teniposide

PTG

[5R-[5Alpha,5a beta,8a alpha, 9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one

Vumon

Thenvlidene-Lignan-P

Vehem

Thenylidene-Lignan-P

VM-26

4'-Demethylepipodophyllotoxin 9-(4,6-O-2-Thenylidene-beta-D-glucopyranoside)

VM26

4'-Demethylepipodophyllotoxin-beta-D-thenylidine Glucoside

EPT

A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C857" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C857" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000043671

PTG

[5R-[5Alpha,5a beta,8a alpha, 9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one

Vumon

Thenvlidene-Lignan-P

Vehem

Thenylidene-Lignan-P

VM-26

4'-Demethylepipodophyllotoxin 9-(4,6-O-2-Thenylidene-beta-D-glucopyranoside)

VM26

4'-Demethylepipodophyllotoxin-beta-D-thenylidine Glucoside

EPT

29767-20-2

http://purl.bioontology.org/ontology/PDQ/CDR0000041034

http://purl.bioontology.org/ontology/PDQ/CDR0000040807

http://purl.bioontology.org/ontology/PDQ/CDR0000039461

http://purl.bioontology.org/ontology/PDQ/CDR0000039037

http://purl.bioontology.org/ontology/PDQ/CDR0000041831

http://purl.bioontology.org/ontology/PDQ/CDR0000041501

http://purl.bioontology.org/ontology/PDQ/CDR0000040937

http://purl.bioontology.org/ontology/PDQ/CDR0000041040

http://purl.bioontology.org/ontology/PDQ/CDR0000041737

http://purl.bioontology.org/ontology/PDQ/CDR0000039776

http://purl.bioontology.org/ontology/PDQ/CDR0000039780

http://purl.bioontology.org/ontology/PDQ/CDR0000039589

http://purl.bioontology.org/ontology/PDQ/CDR0000040254

http://purl.bioontology.org/ontology/PDQ/CDR0000038868

http://purl.bioontology.org/ontology/PDQ/CDR0000039462

http://purl.bioontology.org/ontology/PDQ/CDR0000041934

http://purl.bioontology.org/ontology/PDQ/CDR0000040283

http://purl.bioontology.org/ontology/PDQ/CDR0000037875

http://purl.bioontology.org/ontology/PDQ/CDR0000040930

http://purl.bioontology.org/ontology/PDQ/CDR0000040663

http://purl.bioontology.org/ontology/PDQ/CDR0000038630

http://purl.bioontology.org/ontology/PDQ/CDR0000041007

http://purl.bioontology.org/ontology/PDQ/CDR0000041833

http://purl.bioontology.org/ontology/PDQ/CDR0000038930

http://purl.bioontology.org/ontology/PDQ/CDR0000039036

http://purl.bioontology.org/ontology/PDQ/CDR0000040901

http://purl.bioontology.org/ontology/PDQ/CDR0000040155

http://purl.bioontology.org/ontology/PDQ/CDR0000039513

http://purl.bioontology.org/ontology/PDQ/CDR0000039343

http://purl.bioontology.org/ontology/PDQ/CDR0000039464

C0039512

C0728981

C0733482

C0733481

2006-12-28

A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C857" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C857" NCI Thesaurus)

9336

917

TRD

C857

CDR0000043671

122819

Drug/agent

teniposide

T109

T121